- Page 1 and 2:
Basel Seminars in Pathology Postgra
- Page 3 and 4:
UPDATE ON PATHOLOGY STANDARDS FOR B
- Page 5 and 6:
Molecular Pathways for Bladder Canc
- Page 7:
HISTOLOGIC GRADE UROTHELIAL NEOPLAS
- Page 10 and 11:
What’s New in the 2012 Consensus
- Page 12 and 13:
Reporting of Bladder Cancer • Gui
- Page 14 and 15:
• Seen with instrumentation with
- Page 16 and 17:
Squamous Metaplasia • Should be r
- Page 18 and 19:
GRADING OF UROTHELIAL LESIONS • F
- Page 20 and 21:
NORMAL
- Page 22 and 23:
Urothelial Dysplasia • Overall fe
- Page 24 and 25:
Urothelial Dysplasia • The diagno
- Page 28:
ATYPIA OF UNKNOWN SIGNIFICANCE (WHO
- Page 31 and 32:
Grading of Urothelial Carcinoma •
- Page 33 and 34:
Papilloma
- Page 35 and 36:
PUNLMP
- Page 37 and 38:
LOW GRADE
- Page 39 and 40:
HIGHGRADE
- Page 41 and 42:
P A P I L O M A L M P L O W G R A D
- Page 43 and 44:
Courtesy R. Montironi, Italy Exophy
- Page 45 and 46:
Inverted High Grade without invasio
- Page 47 and 48:
Inverted Papilloma
- Page 49 and 50:
Inverted PUNLMP
- Page 51 and 52:
Inverted LG
- Page 53 and 54:
Inverted HG
- Page 55 and 56:
Inverted HG, Non Inv
- Page 57 and 58:
WHO (2004) /ISUP : Prognostic Signi
- Page 59 and 60:
Contributions of WHO (2004) /ISUP
- Page 61 and 62:
Handling grade heterogeneity in bla
- Page 63 and 64:
Grading Papillary Urothelial Neopla
- Page 65:
Papillary Hyperplasia with Cytologi
- Page 68 and 69:
Dysplasia with early papillary feat
- Page 70 and 71:
Grading Invasive Cancer • Practic
- Page 74 and 75:
• 2 types of muscle - awareness i
- Page 76 and 77:
Muscularis Mucosae Muscle • Hyper
- Page 78 and 79:
M. mucosae muscle patterns Typical
- Page 80 and 81:
M. mucosae muscle pattern Hypertrop
- Page 82 and 83:
Muscularis Propria • Several term
- Page 84 and 85:
Muscle Involved by UCa, Indetermina
- Page 88 and 89:
Assessment of pT2 vs. pT3 - cystect
- Page 91 and 92:
Microinvasive Urothelial Carcinoma
- Page 93 and 94:
Substratification or Substaging of
- Page 95 and 96:
Extensive invasion
- Page 97 and 98:
Retraction a mimic of vascular-lymp
- Page 99 and 100:
Vascular Lymphatic Invasion (LVI)
- Page 101 and 102:
2013 International Society of Urolo
- Page 103 and 104:
Lymph node involvement: • Approx.
- Page 105 and 106:
THE BEST BLADDER CANCER PATHOLOGY S
- Page 107 and 108:
PSEUDONEOPLASTIC MIMICS OF BLADDER
- Page 109 and 110:
EMPHYSEMATOUS & BULLOUS CYSTITIS
- Page 113 and 114:
AMYLOIDOSIS
- Page 115 and 116:
MALAKOPLAKIA
- Page 117:
NORMAL PARAGANGLIONIC TISSUE
- Page 123 and 124:
CIS
- Page 125:
REACTIVE ATYPIA History of stones,
- Page 130:
CIS REACTIVE ATYPIA
- Page 134 and 135:
RADIATION ATYPIA
- Page 136:
INTRAVESICAL THERAPY
- Page 141:
Polyoma Virus Infection • Usually
- Page 149 and 150:
Papillary tumor Micropapillary U Ca
- Page 151 and 152:
Low magnification distinction Broad
- Page 153:
Cystoscopic & microscopic mimic Pap
- Page 158 and 159:
Papillary Polypoid cystitis
- Page 161 and 162:
ALL THAT IS PAPILLARY BLADDER IS NO
- Page 165 and 166:
Bladder Biopsy Interpretation, 2nd
- Page 167 and 168:
TIGHTLY CLUSTERED UROTHELIUM
- Page 169 and 170:
TIGHTLY CLUSTERED UROTHELIUM
- Page 171 and 172:
U Ca. with small tubules Nephrogeni
- Page 173 and 174:
NEPHROGENIC ADENOMA - THE BIG MIMIC
- Page 175:
NEPHROGENIC ADENOMA
- Page 181:
NEPHROGENIC ADENOMA
- Page 185 and 186:
NEPHROGENIC ADENOMA Clues to benign
- Page 187 and 188:
FLORID REACTIVE PROLIFERATIONS norm
- Page 195:
POST-RADIATION PSEUDOCARCINOMATOUS
- Page 214:
LORID CYSTTTIS GLANDULARIS ITH MUCI
- Page 222:
MULLERIANOSIS • Endometriosis, en
- Page 233 and 234:
PSEUDOSARCOMATOUS MYOFIBROBLASTIC P
- Page 235:
Gross PMP • Exophyticpolypoid mas
- Page 246 and 247:
ROLE OF IMMUNOHISTOCHEMISTRY IN THE
- Page 248 and 249:
PROVING UROTHELIAL DIFFERENTIATION
- Page 250 and 251:
CA in the bladder, h.o of lung canc
- Page 252 and 253:
Paraganglioma Epith. LMS PEComa Mel
- Page 255 and 256:
p63
- Page 257 and 258:
Plasmacytoid U Ca
- Page 259 and 260:
• Markers of urothelium and uroth
- Page 261 and 262:
S100P S100P GATA3 GATA3 A-F: S100P,
- Page 263 and 264:
GATA 3 & S100 P: Diagnostic utility
- Page 265 and 266:
PARAGANGLIOMA
- Page 267:
Identification of Succinate Dehydro
- Page 270 and 271:
CIS REACTIVE
- Page 272 and 273:
NORMAL
- Page 274 and 275:
CK-20
- Page 276 and 277:
REACTIVE UROTHELIUM
- Page 278 and 279:
CK-20
- Page 280 and 281:
Reactive CD44
- Page 282 and 283:
CA-INSITU
- Page 284 and 285:
CK-20
- Page 286 and 287:
CIS CK20
- Page 288 and 289:
CK20 (+) CD44(-)
- Page 290 and 291:
p53
- Page 292 and 293:
CD44
- Page 294 and 295:
Reactive CIS
- Page 296 and 297:
Radiation-Reactive Radiation CIS
- Page 298 and 299:
AUA GUIDELINE 2007 UPDATE: • Stan
- Page 300 and 301:
Typical pattern: • Arranged in gr
- Page 302 and 303:
Muscularis mucosae or muscularis pr
- Page 304:
Am J Surg Pathol. 2009 ;33:91-8 SMO
- Page 307 and 308:
Smoothelin hyperplastic
- Page 309 and 310:
Smoothelin
- Page 311 and 312:
SMA - M. Mucosae
- Page 313 and 314:
Smoothelin
- Page 315 and 316:
CAUTERY: MINIMAL EFFECT ON IHC
- Page 318 and 319:
M. Mucosae vs. M. Propria in TURBT
- Page 321 and 322:
M. Mucosae vs. M. Propria in TURBT
- Page 323 and 324:
Smoothelin: Negative - Suggestive o
- Page 325:
Courtesy: Dr John Eble
- Page 329 and 330:
METASTASIS TO THE BLADDER Prostate
- Page 331 and 332:
?Urothelial Carcinoma vs. ?Prostati
- Page 333 and 334:
Concurrent PCa & UCa
- Page 335 and 336:
PCa PCa NKX3.1 P501S PSMA
- Page 338:
100% 100% 90% 88% 88% 88% 80% 70% 6
- Page 342 and 343:
Clear cell Ca Neph. adenoma
- Page 344 and 345:
U Ca. with small tubules Nephrogeni
- Page 346 and 347:
Nephrogenic adenoma Clear cell aden
- Page 348 and 349:
CCCa Pax 2 S100A1 Ki67
- Page 350 and 351:
P Ca A Pax 2 S100A1 Ki67
- Page 352 and 353:
PMP / Pseudotumors
- Page 354 and 355:
SMA
- Page 356:
Sarcomatoid urothelial carcinoma
- Page 361:
Leiomyosarcoma
- Page 365 and 366:
Spindle cell lesions Benign (PMP) v
- Page 367:
SARC CA p63 CK 5/6 or HMCK p63
- Page 370 and 371:
Session plan Renal Pathology for th
- Page 372 and 373:
Tubules - Normal
- Page 374 and 375:
Interstitial inflammation - tubuloi
- Page 376 and 377:
Tubulointerstitial nephritis Classi
- Page 378 and 379:
CKD, previous tuberculosis, HCV pos
- Page 380 and 381:
AKI, ANCA positive, cortex - TIN, g
- Page 382 and 383:
Male 59 years. Acute rise in creati
- Page 384 and 385:
35 patients with IgG4-TIN: 27 (77%)
- Page 386 and 387:
Male 70 years AKI Diagnosis?
- Page 388 and 389:
Hantavirus nephropathy
- Page 390 and 391:
Male, 57 years. Acute renal failure
- Page 392 and 393:
Ascending infection (pyelonephritis
- Page 394 and 395:
Tubulointerstitial infiltrates in t
- Page 396 and 397:
Tubulointerstitial infiltrates in t
- Page 398 and 399:
Things in tubules Casts, crystals,
- Page 400 and 401:
Acute phosphate nephropathy First c
- Page 402 and 403:
Diagnosis?
- Page 404 and 405:
Acute tubular injury Ischaemia, dru
- Page 406 and 407:
Light chain tubulopathy
- Page 408 and 409:
Acute tubular injury in the post mo
- Page 410 and 411:
Acute tubular injury in the post mo
- Page 412 and 413:
Drug-associated tubular injury Drug
- Page 414 and 415:
Gentamicin toxicity Diagnosis?
- Page 416 and 417:
Drug-associated tubular injury Mech
- Page 418 and 419:
Glomerular lesions Ian Roberts Oxfo
- Page 420 and 421:
Tumour nephrectomy specimens Things
- Page 422 and 423:
Glomeruli- Normal
- Page 424 and 425:
Nodular glomerulosclerosis Diabetic
- Page 426 and 427:
Diabetic nephropathy: thickened bas
- Page 428 and 429:
Diabetic nephropathy: Diffuse mesan
- Page 430 and 431:
Diabetic nephropathy: Insudative le
- Page 432 and 433:
Amyloidosis Congo red
- Page 434 and 435:
Amyloidosis
- Page 436 and 437:
Amyloidosis
- Page 438 and 439:
Immunotactoid Fibrillary GN 0.06% o
- Page 440 and 441:
Light chain deposition disease
- Page 442 and 443:
Focal segmental glomerulosclerosis
- Page 444 and 445:
Focal segmental glomerulosclerosis
- Page 446 and 447:
Focal segmental glomerulosclerosis
- Page 448 and 449:
Glomerular lesions: proliferation M
- Page 450 and 451:
Glomerular lesions: proliferation E
- Page 452 and 453:
The diagnosis of IgA nephropathy is
- Page 454 and 455:
The histology of IgA nephropathy is
- Page 456 and 457:
Mesangiocapillary GN = Membranoprol
- Page 458 and 459:
Mesangiocapillary GN, type I C3
- Page 460 and 461:
C3 glomerulopathy MPGN and C3 glome
- Page 462 and 463:
Dense deposit disease
- Page 464 and 465:
Glomerular lesions: necrosis Ruptur
- Page 466 and 467:
Renal vasculitis May be isolated re
- Page 468 and 469:
Renal vasculitis European vasculiti
- Page 470 and 471:
Anti-GBM disease Autoantibodies to
- Page 472 and 473:
Remember: multiple pathologies are
- Page 474 and 475:
Male 46 years. Suffered from diabet
- Page 476 and 477:
Diagnoses: Diabetic nephropathy Oxa
- Page 478 and 479:
Interactive Kidney Quiz Ian S. Robe
- Page 480 and 481:
Test vote How did you learn about t
- Page 482 and 483:
Set 1
- Page 484 and 485:
PathoPic B
- Page 486:
PathoPic D
- Page 490 and 491:
What is your main diagnosis? 1. chr
- Page 492 and 493:
What is your main diagnosis? 1. amy
- Page 494 and 495:
What is your main diagnosis? 1. no
- Page 496 and 497:
A PathoPic Dg: arteriolosclerosis,
- Page 498 and 499:
Dg: diabetic kidney C PathoPic
- Page 500 and 501:
Dg: malignant nephrosclerosis E
- Page 502 and 503:
RCPath “Minimum” dataset for tu
- Page 504 and 505:
Patterns of scarring Granular subca
- Page 506 and 507:
Patterns of scarring Granular subca
- Page 508 and 509:
Deep pitted cortical scars: Pattern
- Page 510 and 511:
Patterns of scarring Deep pitted co
- Page 512 and 513:
Patterns of scarring Segmental tran
- Page 514 and 515:
Malignant hypertension A cause of a
- Page 516 and 517:
Malignant hypertension A cause of a
- Page 518 and 519:
Malignant hypertension A cause of a
- Page 520 and 521:
Malignant vs benign vascular diseas
- Page 522 and 523:
PathoPic G
- Page 524:
PathoPic I
- Page 528 and 529:
What is your main diagnosis? 1. gou
- Page 530 and 531:
What is your main diagnosis? 1. met
- Page 532 and 533:
What is your main diagnosis? 1. ren
- Page 534 and 535:
Solutions (M.J. Mihatsch)
- Page 536 and 537:
Descripition Involvement of cortex
- Page 538 and 539:
Description Whitish discoloration a
- Page 540 and 541:
Description Massive enlargement of
- Page 542 and 543:
Description Brownish discoloration
- Page 544 and 545:
Papillary necrosis Pg: i.e. vascula
- Page 546 and 547:
Papillary necrosis Pg: i.e. vascula
- Page 548 and 549:
Types of papillary necrosis: Extend
- Page 550 and 551:
Black papillary necrosis Think of p
- Page 552 and 553:
Phenacetin kidney Compete necrosis
- Page 554 and 555:
Phenacetin kidney Note massive base
- Page 556 and 557:
Phenacetin kidney Note: Massive lip
- Page 558 and 559:
Typical examples of papillary necro
- Page 560 and 561:
White papillary necrosis Think of v
- Page 562 and 563:
Red papillary necrosis Think of vas
- Page 564 and 565: I hope you will never overlook papi
- Page 566 and 567: Challenges for Pathologists Renal M
- Page 568: Do the morphotypes of RCC have prog
- Page 571 and 572: Potential of Needle Biopsy • Diag
- Page 573 and 574: Novel renal tumor types with clear
- Page 575 and 576: Am J Surg Path 28, 2004 41 Carcinom
- Page 578 and 579: Should Acquired Cystic Disease- RCC
- Page 580 and 581: Clear cell papillary RCC has: 1. PO
- Page 582 and 583: Which name should be used for 1. Cl
- Page 585 and 586: 1. Yes 2. No Should Thyroid-Like Fo
- Page 587 and 588: If focal (
- Page 589 and 590: Denote AMLs with epithelioid morpho
- Page 591: Differential Diagnosis of Cystic Re
- Page 594 and 595: smaller cysts with phyllodes glands
- Page 596 and 597: Are Cystic Nephroma and Mixed Epith
- Page 598 and 599: If you consider CN and MEST variati
- Page 600 and 601: Should Tubulocystic-RCC be recogniz
- Page 602 and 603: Prognosis • Type • Stage • Gr
- Page 604: Papillary renal cell carcinoma Type
- Page 608 and 609: Differential Diagnosis: metanephric
- Page 610 and 611: The distinction between type 1 vers
- Page 612 and 613: Should Oncocytic Papillary-RCC be r
- Page 617 and 618: Should HLRCC be Recognized as a Dis
- Page 619 and 620: Grading of Chromophobe RCC Amin MA,
- Page 621 and 622: How should we grade papillary RCC?
- Page 624 and 625: Unlike the Skywalker family, once t
- Page 626 and 627: Survival (%) Prognostic Relevance o
- Page 628 and 629: If a Tumor Shows Sarcomatoid Morpho
- Page 630 and 631: Tumor Staging Bonsib SM. Renal lymp
- Page 632 and 633: For staging purposes, do you consid
- Page 634 and 635: Should the component of necrosis be
- Page 636 and 637: Challenges for Pathologists Diagnos
- Page 638 and 639: A proposed marker-based strategy de
- Page 640 and 641: VHL and tumor development Frew and
- Page 643 and 644: Randomised studies in the first lin
- Page 645 and 646: J Urology 180, pp. 860-866, 2008
- Page 647 and 648: Frequenz VHL Mutation in clear cell
- Page 649 and 650: Thank you
- Page 652 and 653: Potential of Needle Biopsy • Diag
- Page 657 and 658: Hereditary Renal Cancer Syndromes
- Page 660 and 661: How should HOCT be recognized? 1. S
- Page 662 and 663: Novel renal tumor types with clear
- Page 664 and 665:
Renal Tumors with Clear Cytoplasm A
- Page 666 and 667:
CA IX and Tumor Development Mutatio
- Page 668 and 669:
Montani et al.: Am J Surg Path, May
- Page 670 and 671:
Is loss of VHL sufficient to cause
- Page 672 and 673:
Inside the primary cilium Receptors
- Page 674 and 675:
a b c d e f Montani et al.: Am J Su
- Page 676 and 677:
Additional mutation in VHL-/- cells
- Page 678 and 679:
Is it Acceptable for MC-RCC to have
- Page 680 and 681:
Renal Cyst in ADPKD Ki-67
- Page 682 and 683:
Novel renal tumor types with clear
- Page 684 and 685:
TFE3-Proteine-Expression
- Page 686 and 687:
• 14/28 pts: Stage 4 • 11/13 pt
- Page 689 and 690:
Translocation Carcinomas (MiTF/TFE
- Page 691:
When should TFE3 and TFEB analysis
- Page 694:
Clear cell-papillary RCC, sporadic
- Page 698 and 699:
Differential Diagnosis of Cystic Re
- Page 701 and 702:
Are Cystic Nephroma and Mixed Epith
- Page 703 and 704:
smaller cysts with phyllodes glands
- Page 705 and 706:
Immunohistochemistry MTSC (%) Papil
- Page 707 and 708:
Which IHC marker do you think is th
- Page 709 and 710:
PAX2 expression pattern in 16 spora
- Page 711 and 712:
PAX2 expression and overall surviva
- Page 715 and 716:
Tumors with Spindle Cell Morphology
- Page 717:
Small Blue Round Cell Tumors of Kid
- Page 720 and 721:
CD-99
- Page 724:
CD 99 Ewing-Sarcoma/PNET
- Page 728 and 729:
Synaptophysin
- Page 731:
The future has arrived 82
- Page 734:
VHL and Deep Sequencing • several
- Page 737 and 738:
Loss of PBRM1 expression is correla
- Page 739 and 740:
Cell Surface Capturing Proteomics:
- Page 741:
Conclusions •Renal mass biopsy -